Phase II evaluation of fludarabine in patients with metastatic breast cancer: a Southeastern Cancer Study Group trial.
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001088:Arabinonucleotides / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D001084:Vidarabine Phosphate / Q000031:analogs & derivatives / Q000627:therapeutic use*
D000964:Antimetabolites, Antineoplastic; D001088:Arabinonucleotides; D001084:Vidarabine Phosphate; C042382:fludarabine phosphate